The Institute of Medicine identified a need for an international agreement to reduce the amount of falsified, substandard and counterfeit pharmaceuticals in a new report.
At the request of the Food and Drug Administration, an IOM committee examined the global effects of falsified, substandard and counterfeit drugs in a report, "Countering the Problem of Falsified and Substandard Drugs."
Click here to read the full report on IOM's recommendations in Becker's ASC Review.
At the request of the Food and Drug Administration, an IOM committee examined the global effects of falsified, substandard and counterfeit drugs in a report, "Countering the Problem of Falsified and Substandard Drugs."
Click here to read the full report on IOM's recommendations in Becker's ASC Review.